| First Posted | New Trial Filing | Phase | Status |
|---|---|---|---|
| 2026-06-08 | NCT07634094 Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT00003641 | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | Melanoma (Skin) | Active, Not Recruiting |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or… | Clinical Stage III Cutaneous Melanoma AJCC v8 | Active, Not Recruiting |
| NCT00569127 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients… | Colorectal Neuroendocrine Tumor G1 | Active, Not Recruiting |
| NCT01274338 | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage… | Melanoma of Unknown Primary | Active, Not Recruiting |
| Phase 2 | |||
| NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients… | Recurrent Melanoma | Active, Not Recruiting |
| NCT07634094 | Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and… | Ovarian Cancer | Not Yet Recruiting |
| NCT03899987 | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With… | Prostate Adenocarcinoma | Active, Not Recruiting |